| INTRODUCTION
Curcumin ((1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); C 21 H 20 O 6 ; M.W. 368.38) is a polyphenolic compound that could be extracted from dried rhizomes of turmeric (Curcuma longa). Turmeric is widely used as a food component in distinct parts of the world, including Southeast Asia, China, and India (X. S. Wang, Zhang, et al., 2017) . The medicinal properties of curcumin have been known for ages and listed in Sushruta Samhita (sixth century BC) and Charaka Samhita (300-500 BC; Bandyopadhyay, 2014) . These two ancient books describe the Ayurveda cure of diverse body ailments. According to Sushruta Samhita, curcumin is a wound healer that also helps in relieving the effect of poisoned food. Curcumin is an "Indian solid Gold" and "Spice of Life," due to its beneficial and multitargeted effects in multiple disorders of the body (Aggarwal, Sundaram, Malani, & Ichikawa, 2007) .
Curcumin is useful in different central nervous system disorders of the body, at least in the preclinical studies (Morales, Cerda- Troncoso, Andrade, & Maccioni, 2017; Shen, Wei, Li, Qiao, & Li, 2017; J. Wang, Liu, et al., 2017; Y. Zhang et al., 2017) . This highly lipophilic molecule either per se or in different formulations could cross the blood-brain barrier (Chiu et al., 2011; Schiborr, Eckert, Rimbach, & Frank, 2010; X. Zhang, Tian, et al., 2014) . In normal mice, the brain uptake of intravenously injected radioactive curcumin could be observed at 2 min, which becomes undetectable after 30 min of its administration (Ryu, Choe, Lee, Choi, & Kim, 2006) . The exact mechanism of its neuroprotective effect is unclear. Nonetheless, curcumin may affect different growth and transcription factors, enzymes, and cytokines during its brief stay in the brain (Aggarwal et al., 2007) . It is well known that curcumin is an inhibitor of nuclear factor κB and a potent inducer of heme oxygenase 1 protein (Carmona-Aparicio et al., 2015; Hill-Kapturczak, Thamilselvan, Liu, Nick, & Agarwal, 2001; Xie et al., 2017) . Both of these factors play an essential role in inflammation and oxidative stress in the body.
Epilepsy (disorder) is a chronic neurological disorder characterized by recurrent unprovoked seizures (symptom). Seizures can be divided into two broad categories: (a) generalized and (b) partial.
Generalized seizures involve the whole brain, whereas partial seizures are focal in nature. Sometimes, these generalized seizures are the consequence of secondary generalization of partial or focal seizures. About 26 anti-epileptic medications are available that has resulted in well-controlled epilepsy (both partial and generalized) in about two thirds of the patients. However, besides these drug availability, about one third of these patients continue to suffer from this disorder and considered to be in the state of refractoriness (Tang, Hartz, & Bauer, 2017) . Although we are efficient in managing seizures, however, it is highly challenging to correct the underlying pathophysiological basis of epilepsy (Wong, 2010) . Furthermore, the existing anti-epileptic drugs have side effects and adverse effects that may be bothersome on their long-term use. Some of these existing anti-epileptic molecules may even result in the hepatotoxicity (Vidaurre, Gedela, & Yarosz, 2017) . Recent preclinical studies have indicated that curcumin might be useful in epilepsy and its associated disorders without any problematic side effects or adverse effects (Drion et al., 2016; H. Kaur, Patro, Tikoo, & Sandhir, 2015) . According to FDA allometric scaling (https://www.fda.gov/downloads/ drugs/guidances/ucm078932.pdf), a 100-mg/kg effective dose of curcumin in mice corresponds to 8-mg/kg human equivalent dose.
If an average human weight is 70 kg, the effective dose of curcumin in human is about 560 mg. This dose in humans is safe to administer.
In a Phase I clinical study, a daily dose of 3,600-8,000 mg for at least 4 months did not result in any serious side effects, except mild nausea and diarrhea (Hsu & Cheng, 2007) .
Curcumin possesses two aryl rings that contain methoxy phenolic OH-groups at the ortho position and is symmetrically linked to a β-diketone moiety (Lee et al., 2013) . It has poor brain reachability that limits its use in clinics. Curcumin is metabolized by the liver and excreted through the kidneys so that lesser amount is available to reach the brain. In Phase II clinical trial, curcumin displayed a poor bioavailability with plasma levels of 22-41 ng/ml, plateaued over a 4-week period when administered at a dose of 8 g/day (Dhillon et al., 2008) . Drion et al. (2016) demonstrated the rapid metabolism of curcumin in Sprague-Dawley rats. The authors could not detect the free curcumin level in the blood even 2 hr after a 400-mg/kg dose of curcumin (Drion et al., 2016) . Nevertheless, they could easily detect the levels of its metabolites such as curcumin glucuronide and curcumin sulfate (Drion et al., 2016) .
The present review describes the anti-epileptic properties of curcumin, and the emphasis has been given to the preclinical evidence describing its anti-epileptic potential with the possible mechanism of action. Additionally, the bioavailability issue with the use of curcumin as an anti-epileptic molecule is discussed in this article.
| ANTI-INFLAMMATORY AND ANTIOXIDANT EFFECTS OF CURCUMIN
Curcumin is a potent antioxidant and anti-inflammatory molecule (Ak & Gulcin, 2008; Barclay et al., 2000; Desai & Patravale, 2017; Menon & Sudheer, 2007) . The neuroinflammation and oxidative stress are the two principal pathophysiological hallmarks of epilepsy and seizure disorders (Huang et al., 2017; Wyatt, Witt, Barbaro, CohenGadol, & Brewster, 2017) . It has been shown that these prolonged seizures could activate microglia and astrocytes, which may release various inflammatory molecules perpetuating hyper-excitability, neuronal cell death, and epileptogenesis (Vezzani, French, Bartfai, & Baram, 2011) . As a matter of fact, these proinflammatory cytokines and other neuroinflammatory markers could be seen in both experimental models of epilepsy and human clinical cases (Koh, 2018) .
Neuroinflammation is a contributing factor in some focal onsetpharmacoresistance epilepsies (Terrone, Salamone, & Vezzani, 2017) . Our earlier studies also support the fact that anti-inflammatory molecules are useful in the management of epilepsy (Akula, Dhir, & Kulkarni, 2008; Dhir, Naidu, & Kulkarni, 2007) . Anti-inflammatory molecules such as cyclooxygenase (COX) inhibitors, particularly preferential or selective COX-2 inhibitors, increased the onset of seizures with respect to their vehicle control group in animal models of epilepsy (Dhir, Naidu, & Kulkarni, 2006) . Curcumin through its ability to inhibit the expression of different inflammatory markers such as COX-2, lipoxygenase, and inducible nitric oxide synthase (NOS) might be useful in epilepsy and related disorders (Menon & Sudheer, 2007) .
There are various studies in the literature that indicates the potent antioxidant property of curcumin with relevance to epilepsy disorders. In Drosophila melanogaster, curcumin (0.2 and 1.0 mg/g of diet for at least 7 days) elevated the levels of superoxide dismutase, an antioxidant enzyme that might have partly contributed to the increased lifespan in these flies (Akinyemi, Oboh, Ogunsuyi, Abolaji, & Udofia, 2017) . In the chronic pentylenetetrazol (PTZ)-treated animals, there is an increased expression of both GFAP (glial fibrillary acidic protein, a biomarker for astrocytic activation) and Iba-1 (ionized calcium binding adaptor molecule 1, a biomarker for microglial activation; H. Kaur et al., 2015) . Also, in these animals, an increase in the expression of cytokines (such as interleukin 1β, interleukin 6, and tumor necrosis factor alpha) and chemokines (such as monocyte chemoattractant protein 1) could be seen in both cortex and hippocampus regions of the brain (H. Kaur et al., 2015) . Curcumin at a daily dose of 100 mg/kg for 40 days reduced the levels of these cytokines and chemokines. Markedly, there is a reduction of both GFAP-1 and Iba-1 markers, suggesting the anti-inflammatory potential of curcumin in this animal model (H. Kaur et al., 2015) . In the PTZ kindling model of epilepsy, curcumin (50-200 mg/kg po) has an ability to reduce the elevated levels of both malondialdehyde (MDA) and glutathione, thus displaying antioxidant ability (Agarwal, Jain, Agarwal, Mediratta, & Sharma, 2011) . Ezz, Khadrawy, and Noor (2011) have also demonstrated the antioxidant effect of curcumin in pilocarpine challenged rats. Curcumin was given to these rats for 21 days at a dose of 80 mg/kg po. These studies definitely support the hypothesis that curcumin has an antioxidant and anti-inflammatory properties that are beneficial for its anti-seizure or anti-epileptic effect.
| PRECLINICAL STUDIES WITH CURCUMIN IN EPILEPSY
Animal models of epilepsy (both acute and chronic) are routinely used to discover the anti-seizure efficacy and potency of newly discovered The anti-seizure potential of curcumin is demonstrated in different animal models of epilepsy (listed in Table 1 ). The genomics-based drug repurposing technique has listed curcumin as a potential anti-epileptic drug (Mirza, Sills, Pirmohamed, & Marson, 2017) . The anti-epileptic activity of curcumin identified through this technique was further confirmed by the different preclinical evidences available in the literature:
| Acute animal models of seizures
Curcumin is protective in raising the seizure threshold when administered acutely as a single dose. In an increasing current electroshock test model in mice, curcumin at a dose of 100 mg/kg when administered orally raised the seizure threshold and the effect could be visible after both acute and chronic administration (for 21 days; Bharal et al., 2008) . The effect of curcumin in this animal model was found similar to phenytoin (25 mg/kg po) in increasing the seizure threshold (Bharal et al., 2008) . In this study, the authors did not find any protection in Protective curcumin is administered before any seizure challenge. Therapeutic curcumin is administered after seizures are already set in animals.
the postictal mortality after acute doses of curcumin in a dose range of 50-200 mg/kg po. Nevertheless, chronic administration of curcumin protected these animals from mortality in this animal model, suggesting that there is a strong potential of curcumin as an anticonvulsant agent (Bharal et al., 2008) . The authors further found an anxiogenic effect of curcumin when administered acutely at a dose of 100 mg/ kg po but the effect disappeared after its chronic administration (Bharal et al., 2008) .
The antioxidant and acute anti-seizure potential of curcumin was also demonstrated by Du et al. (2012) . These authors have documented the anticonvulsant effect of curcumin at doses of 100 and 300 mg/kg against pilocarpine seizures in rats. The anticonvulsant effect of curcumin in this model might be due to its antioxidant potential, especially through modulating the effect on NOS enzyme (Du et al., 2012) . In the pilocarpine challenged rats, the authors perceived an increase in the levels of MDA, NOS, and lactate dehydrogenase and reduction in the levels of glutathione and superoxide dismutase. Curcumin administration reversed all the altered oxidative stress parameters, except MDA levels in these rats (Du et al., 2012) .
Similarly, curcumin (50-200 mg·kg
) is neuroprotective in the lithium-pilocarpine animal model in postnatal 20-day-old rats (Ahmad, 2013) . Pilocarpine is a cholinergic agonist. The anti-seizure effect of curcumin in lithium-pilocarpine-induced status epilepticus is not fully understood; however, the antioxidant ability of curcumin might be responsible for such effects. Curcumin in this study reversed the raised MDA levels in this animal model. Additionally, curcumin attenuated the reduction in reduced glutathione levels (Ahmad, 2013) , demonstrating its strong antioxidant potential.
Curcumin is also effective in animal models of status epilepticus (Gupta et al., 2009) Curcumin is protective in both chemical and electrical kindling procedures. The detailed procedure of both chemical and electrical kindling is described elsewhere (Dhir, 2012) . In the kindling procedure, a repetitive application of the subconvulsant stimuli, either in the form of chemical or electric insult, over several days may ultimately lead to full-blown seizures (Dhir, 2012) . The animals at this stage would be known as "kindled." This is a chronic model of preclinical epilepsy, and different novel molecules could be tested for their anti-epileptic properties (Dhir, 2012) . PTZ and amygdala kindling procedures are the two widely used animal models to screen anti-epileptic drugs (Dhir, 2012) . In one study with the electrical kindled animals (amygdala electrical kindling procedure), curcumin at doses of 100 and 300 mg·kg −1 ·day −1 was found extremely protective in preventing the development of epilepsy (Du et al., 2009) . In this procedure, stimulation of amygdala region of the rat brain with after-discharge threshold intensity plus 100 μA once a day for 5 days in a week for 21 days via an implanted electrode resulted in the development of kindling.
Curcumin at different doses administered daily 30 min before the electric current could prevent epileptogenesis in this animal model (Du et al., 2009 ).
Similarly, Mehla et al. (2010) have reported that curcumin at a dose of 300 mg/kg improved the seizure scores and delayed the onset to distinct phases of PTZ seizures, such as myoclonic jerks, clonus, and generalized tonic-clonic seizures in a PTZ kindling procedure carried out in male Wistar rats. These rats become kindled after 31.0 ± 1.4 days of PTZ injections at a dose of 30 mg/kg when administered every alternate day. The authors demonstrated that there is an increase in oxidative stress parameters after PTZ kindling, which could be reversed by curcumin administration . Additionally, these PTZ kindled rats displayed a cognitive decline that was again reversed by curcumin administration . In another similar set of study, the subconvulsant doses of PTZ in rats over a In this study, the authors have not administered any bioavailability enhancing agent, such as piperine (Agarwal et al., 2011) . The authors of this study have found that curcumin could slow down the kindling development in these animals (Agarwal et al., 2011) .
The pilocarpine-induced seizures could also be used as a chronic animal model of epileptogenesis. An intraperitoneal injection of 380-mg/kg dose of pilocarpine in adult male Wistar rats could result in an acute seizure phase followed by development of epilepsy later in life time. As a general procedure, these rats are pretreated with atropine (5 mg/kg) before pilocarpine challenge in order to avoid peripheral muscarinic side effects and mortality. After 40-80 min of pilocarpine challenge, these rats could transition into status epilepticus (Ezz et al., 2011) . The authors found an increase in the levels of nitric oxide and reduction in the glutathione and catalase activity in these rats (Ezz et al., 2011) . The pilocarpine challenge resulted in about 35% mortality; remaining survived animals were kept for 22 days.
These rats were continuously monitored for the signs of spontaneous recurrent seizures (SRS), which is an evidence for epilepsy development. In one of the survived groups, curcumin at a dose of 80 mg·kg
·day −1 when administered per oral for 21 days abolished SRS (Ezz et al., 2011) . Also, curcumin was found protective in reversing various oxidative stress changes associated with pilocarpine challenge (Ezz et al., 2011) .
In a study carried out by Kiasalari et al. (2013) using kainate model of temporal lobe epilepsy, curcumin (100 mg·kg −1 ·day −1 starting 1 week before surgery and the last treatment was 1 hr before the kainate challenge) was found to be protective in reducing the seizure score compared to the vehicle-treated group. An intrahippocampal injection of kainate in these animals resulted in an increase in oxidative stress parameters. Pretreatment of curcumin reversed oxidative stress in these animals (Kiasalari et al., 2013) . The authors did not measure the SRS. Nonetheless, another study showed that curcumin could prevent SRS severity caused due to intrahippocampal kainate administration when tested in adult male Wistar rats . SRS could be developed in these rats within 15-30 days after kainate challenge . Curcumin, when administered during this latent phase, could be useful for preventing these seizure episodes . In this study, curcumin was also administered at a dose of 100 mg·kg −1 ·day −1 for 14 days. Furthermore, curcumin prevented the neuronal loss and astrocytic activation caused due to kainic acid in these rats .
In another model, curcumin was administered as a posttreatment strategy starting the next day after the kainic acid challenge and continued for 7 days followed by gene profiling using microarray tech- The L-arginine nitric oxide pathway might be responsible for the anti-epileptic effect of curcumin, as determined using PTZ kindled rats (Zhu et al., 2015) . Curcumin was administered chronically for 24 days.
It was found that a 200-mg/kg daily dose of this molecule is the most effective one in reducing the epileptiform discharges (Zhu et al., 2015) .
Both L-NAME (N-nitro-L-arginine methyl ester, a nonselective NOS inhibitor) and 7-NI (7-nitroindazole; a selective neuronal NOS inhibitor) augmented the anti-seizure effect of curcumin (Zhu et al., 2015) .
A nitric oxide precursor molecule L-arginine reversed the anti-seizure potential of curcumin at initial stages, but the contrasting effect could be seen at later stages (Zhu et al., 2015) .
In cultured rat hippocampal cells, curcumin inhibited the L-type calcium channels (Liu et al., 2013) . It is unclear if the anti-seizure effect of curcumin requires the participation of these channels. Although not very common, some anti-epileptic drugs work by modulating the functioning of L-type calcium channels. The anticonvulsant effect of cannabidiol is partly through its effect on L-type calcium channels (Naderi et al., 2012) . Besides, curcumin has shown to modulate other ion channels such as voltage-gated potassium and high-voltage gated calcium channels (X. Zhang, Chen, Wang, Peng, & Cai, 2014) , which might contribute towards its protective effect in epilepsy. Curcumin could also result in the reduction of calcium current as demonstrated in SH-SY5Y neuronal cells (Uguz, Oz, & Naziroglu, 2016) . Furthermore, aquaporin-4 channels have been speculated to play an essential role in the neuroprotective effect of curcumin (Laird et al., 2010) . It has been stated that aquaporin-4 channels in the glial cells play a vital role in the excitotoxic process in epilepsy (Binder, Nagelhus, & Ottersen, 2012) .
Curcumin is an inhibitor of mammalian target of rapamycin-raptor complex (mTOR) pathway. The mTOR inhibiting property of curcumin may partly contribute towards its anti-seizure and anti-epileptogenic potential. Rapamycin, an inhibitor of mTOR pathway, has shown to be anti-seizure and anti-epileptogenic (Drion et al., 2016; van Vliet et al., 2012) .
| Curcumin in epilepsy comorbidities
Patients with epilepsy may experience other psychiatric and neurological comorbid disorders such as depression and memory loss (Choudhary et al., 2013) . These disorders crave utmost attention besides treating the epilepsy disorder. The authors in one of the studies documented an effect of curcumin on the depressive illness and cognitive decline in PTZ kindled mice. The results are comparable with phenytoin, a standard sodium channel blocking anti-epileptic drug. The authors achieved that although phenytoin (30 mg/kg) reduced the seizure score and improved the depressive illness score (assessed by the tail-suspension test) in these mice, however, there was no improvement in the cognitive decline (assessed by the passive shock avoidance test; Choudhary et al., 2013) . In contrast, curcumin (100 and 200 mg/kg) not only reduced seizure score and depression-like symptoms but also improved the cognition in these animals (Choudhary et al., 2013) . This is further demonstrated by the levels of different neurotransmitters in the brain of these mice (Choudhary et al., 2013) . The PTZ kindled mice had reduced levels of brain norepinephrine and serotonin that was reversed by curcumin treatment (Choudhary et al., 2013) . Phenytoin did not affect the reduced norepinephrine while it restored the reduced serotonin levels in this animal model (Choudhary et al., 2013) . Both curcumin and phenytoin restored the nitrate levels in this animal model (Choudhary et al., 2013) . In one of our earlier reviews published, the effect of curcumin on various neurotransmitter systems has been discussed in detail (Kulkarni & Dhir, 2010) . It has been discussed by Kulkarni and Dhir (2010) that chronic stress could lead to the reduction of both serotonin and dopamine monoamines in the mouse brain. Chronic administration of curcumin for 21 days at 40 mg/kg could reverse this decrease in serotonin and dopamine levels. By doing so, this molecule possesses antistress and antidepressant-like activities in this animal model (Kulkarni & Dhir, 2010) .
Additionally, some standard anti-seizure drugs, such as carbamazepine and phenobarbitone, are known to cause cognitive decline when used chronically . The authors speculated that a cognitive decline observed with the chronic use of these drugs might be linked to its tendency to induce oxidative stress . To prove this hypothesis, Reeta et al. (2010) administered these drugs (60 mg/kg carbamazepine or 75 mg/kg phenobarbitone) in male Wistar rats for 21 days. The learning and memory parameters were measured using passive avoidance and elevated plus-maze tasks. After behavioral tests, the brains of these rats were removed and estimated for MDA and reduced glutathione level . The authors reported a cognitive decline in these animals as assessed by above-mentioned behavioral tasks. There is an increase in MDA and a reduction in the reduced glutathione level in animals treated with carbamazepine or phenobarbitone . Curcumin, when administered along with these anti-seizure drugs, was found to reverse this cognitive decline as well as oxidative stress parameters .
There might be two possibilities with respect to the mechanism of beneficial effect of curcumin in these comorbid disorders. At the first instance, curcumin through its anti-seizure potential may prevent these secondary outcomes such as depression, anxiety, and other disorders. In the second hypothesis, curcumin's usefulness in these comorbid disorders is independent of its anti-seizure mechanism. Nevertheless, in both cases, curcumin is useful not only for the management of seizures but also comorbid disorders.
| GABAergic and glutamatergic modulation by curcumin
Besides different mechanisms listed above, curcumin could also modulate the levels of GABA and glutamate neurotransmitters in the brain. These two neurotransmitters play a critical role in the pathophysiology of epilepsy. GABA is inhibitory whereas glutamate is an excitatory neurotransmitter in the adult brain. Curcumin (250 and 625 mg/kg) after 2, 4, 6, and 8 weeks of its administration acquires an ability to elevate the levels of GABA, at least in the hypothalamus region of the brain (Nikpour Moghaddam, Qujeq, Rastegari Efahani, & Nikpour Moghaddam, 2015) . However, Gilhotra and Dhingra (2010) did not find any changes in the GABA level in mouse brain after its (10 and 20 mg/kg) administration. These contrary findings might be due to the difference in the doses of curcumin administered in these animals. The molecule could also prevent the glutamate release in the rat prefrontocortical nerve terminals. This effect of curcumin is through reducing the availability of synaptic vesicles for the exocytosis process (Lin, Lu, Huang, & Wang, 2012) . Furthermore, curcumin could also abolish the excitotoxic effect of glutamate by elevating the levels of the brain-derived neurotrophic factor (R. Wang et al., 2008) .
Besides, A. Kaur et al. (2016) speculated that curcumin is an NMDA receptor antagonist. Curcumin could also reverse the glutamate-induced excitotoxicity in the (a) cerebral cortex region of streptozotocin-induced diabetic rats (Jayanarayanan, Smijin, Peeyush, Anju, & Paulose, 2013) , (b) PC12 cells (Chang, Chen, Yu, Peng, & Peng, 2014) , and (c) SH-SY 5Y neuronal differentiated cell culture (Chen, An, Tie, Pan, & Li, 2015) . A study has shown that curcumin could also increase the expression of NMDA receptor subunit type 2A (NR2A), contributing to its neuroprotective effect (Matteucci et al., 2011) .
| INTERACTIONS WITH ANTI-EPILEPTIC DRUGS
Curcumin is lipophilic in nature with a logP value ranging from 2.3 to 2.6 (Heger, van Golen, Broekgaarden, & Michel, 2014) . The transportation of this molecule across the intestinal mucosa into circulation is ineffective (Heger et al., 2014) . Curcumin, which is absorbed into the blood, is immediately transformed by the liver, kidneys, and other organs (Heger et al., 2014) . Consequently, it is hard to detect free curcumin in the plasma of the humans even when it is administered at high doses via an oral route of administration (Heger et al., 2014) .
Curcumin can undergo Phase I (modification) and Phase II (conjugation) metabolites in the enterocytes (intestinal absorptive cells) with the help of several cytosolic and microsomal enzymes. Curcumin can also be the substrate for several proteins in the enterocytes, leading to its poor boavailability. Some metabolites of curcumin include tetrahydrocurcumin, hexahydrocurcumin, octahydrocurcumin, and curcumin glucuronide, vanillin, and ferulic acid (Heger et al., 2014) .
Out of all these metabolites, ferulic acid has been studied for its anticonvulsant and anti-epileptogenic effect (Hassanzadeh, Arbabi, Atyabi, & Dinarvand, 2017) . Ferulic acid possesses anti-epileptogenic activity in a PTZ kindled experiment in rats (Hassanzadeh et al., 2017 ). There are very limited studies evaluating the anticonvulsant effect of vanillin in experimental models of epilepsy (Wu et al., 1989) . Curcumin and its metabolites, tetrahydrocurcumin, hexahydrocurcumin, and octahydrocurcumin, have definitely shown antioxidant and anti-inflammatory activities (Zhao et al., 2015) . However, the contribution of these metabolites in curcumin's anti-epileptic activity is not very clear. (Reeta et al., 2011) . Also, in a separate study, Reeta et al. (2010) have documented no interactions between curcumin and phenobarbitone or carbamazepine when administered chronically for 21 days.
| BIOAVAILABILITY ISSUE WITH CURCUMIN
Curcumin has a very low oral bioavailability. In a randomized, doubleblind, placebo-controlled study involving Alzheimer's patients, a dose up to 4 g/day was not found to be different from the placebo control group (Ringman et al., 2012) . The reason behind this lack of effect might be due to its limited availability to the brain. Drion et al. (2016) have seen that curcumin could neither protect animals from electrical seizures nor shelter them from epileptogenesis induced by electrogenic poststatus epilepticus rat model. The authors again discussed that the reason for the lack of curcumin's anti-epileptogenic activity might be due to its limited availability to the brain tissue (Drion et al., 2016) .
In a 24-week randomized, double-blinded, placebo-controlled study, curcumin C3 complex was found ineffective in patients with mild-to-moderate Alzheimer's disease when administered at a dose of either 2-4 g/day for at least 24 weeks (Ringman et al., 2012) . The formulation consisted of 95% curcuminoids, with 70-80% curcumin, 15-25% demethoxycurcumin, and 2.5-6.5% bisdemethoxycurcumin (Ringman et al., 2012) . The authors considered the low bioavailability of curcumin as a primary cause for the lack of efficacy of curcumin in these patients. A very low plasma level of only 7.32 ng/ml could be detected in these patients (Ringman et al., 2012) .
The brain availability of curcumin could be enhanced by using different techniques. In one of these strategies, cocrystals of curcumin with the antioxidant hydrophilic conformer could be developed and incorporated into the micellar nanocarrier (Desai & Patravale, 2017) .
This formulation could be useful for the intranasal use (Desai & Patravale, 2017) . This product was found to be more brain available with superior antioxidant potency compared with curcumin alone (Desai & Patravale, 2017) . The relative bioavailability was also enhanced to 4.5-6 folds with the micellar and cocrystal micellar formulations (Desai & Patravale, 2017) .
Curcumin nanoparticles can be formulated using chitosan-alginate and sodium tripolyphosphate which enhances its aqueous solubility and ability to penetrate the blood-brain barrier (Hashemian et al., 2017) . When tested in PTZ kindled male NMRI mice, these nanoparticles at much lower dose of curcumin (12.5-25 mg/kg) were found to be effective in reducing the seizure stage and duration. The same doses of curcumin were found ineffective in this animal model (Hashemian et al., 2017) . Additionally, the authors reported that lower doses of 12.5 and 25 mg/kg are effective in ameliorating both microglia and astrocytes activation in the hippocampus region of the brain (Hashemian et al., 2017) . have prepared nanoformulation of curcumin with the help of PLGA (poly(lactic-co-glycolic acid)) using high-pressure emulsification-solvent evaporation method.
The authors asserted that although both curcumin and nanocurcumin could cross the blood-brain barrier, however, the nanocurcumin has a better retention capacity in the hippocampus (increase by 83%) and cerebral cortex (increase by 96%) regions of the brain . This property of nanocurcumin may render us with prolonged anti-seizure effect. The intravenous administration of nanocurcumin yielded higher area under the curve in rat plasma compared with curcumin (Tsai, Jan, et al., 2011) . Furthermore, the oral nanocurcumin has been found to be 22% more bioavailability than curcumin itself (Tsai, Jan, et al., 2011) .
Similarly, curcumin liposomal formulation could be prepared with the rapid injection technique (Agarwal et al., 2013) . The lipid mixture, in this case, has components of lecithin and glycerin. The formulation was tested in multiple seizure tests, including increasing current electroshock seizures, PTZ-induced seizures, and status epilepticus (Agarwal et al., 2013) . Administration of PTZ in rodents does not produce status epilepticus. However, the authors of the present study have administered phenytoin 2 hr before challenging these mice with PTZ (Agarwal et al., 2013) . Phenytoin blocked the tonic hind-limb extension caused due to PTZ thus leading to status epilepticus in these mice. It was found that a lower dose of 25 and 50 mg/kg was found effective in all these animal models of seizures (Agarwal et al., 2013) .
A very recent study has indicated that the micronized curcumin, prepared using the supercritical carbon dioxide processing technique, has superior anti-epileptic activity in both larvae and adult zebrafish.
The effect was comparable to valproate, a standard anti-seizure molecule (Bertoncello et al., 2018) . Curcumin by itself (without micronization) does not prevent or slow-down the onset of tonicclonic seizures in this animal model (Bertoncello et al., 2018) .
| CONCLUSION
Curcumin has an anti-seizure potential in animal models of epilepsy. In particular, doses above 100 mg/kg (acute and chronic) are found to be anticonvulsant in different animal models. Moreover, curcumin may also possess an anti-epileptogenic activity, as it inhibits the development of SRS in some chronic animal models of epilepsy. The crucial issue with its use in clinics is its poor brain availability, and various techniques including the use of nanotechnology have amended this limitation. With the use of these technologies, the effective dose of curcumin in preclinical animal models could be reduced. This particular review also emphasizes carrying out clinical trials with the use of curcumin in epilepsy patients, particularly, as an add-on therapy with standard anti-epileptic drug molecules.
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